MAGE-3 (271-279)

MAGE-3 (271-279) is a synthetic peptide fragment derived from the melanoma-associated antigen 3 (MAGE-3) protein, representing amino acids 271 through 279 of this cancer-testis antigen. As a nonapeptide, it is recognized for its role in immunological studies, particularly those investigating tumor antigenicity, T-cell epitope mapping, and the molecular mechanisms of antigen processing and presentation. Owing to its sequence specificity and immunogenic relevance, this peptide serves as a valuable tool in the exploration of antigen recognition, immune modulation, and peptide-based assay development within cancer research and immunology.

Epitope Mapping: In immunological research, the 271-279 fragment of MAGE-3 is frequently utilized for precise epitope mapping to identify T-cell recognition sites on tumor-associated antigens. By exposing immune cells or antigen-presenting cells to this peptide, investigators can delineate the specific regions of MAGE-3 that are recognized by cytotoxic T lymphocytes (CTLs). This approach provides critical insight into antigenic determinants relevant for tumor immunity, facilitating the rational design of immunotherapeutic strategies and enhancing the understanding of T-cell receptor specificity.

Antigen Presentation Studies: The peptide is instrumental in dissecting the pathways of antigen processing and presentation, particularly in the context of major histocompatibility complex (MHC) class I molecules. Researchers employ this defined sequence to load onto MHC molecules in vitro or in cell-based systems, enabling the evaluation of peptide-MHC stability, binding affinity, and subsequent T-cell activation. Such studies contribute to the broader understanding of how tumor antigens are processed and displayed by cancer cells, informing the development of improved antigen delivery systems and immunomodulatory approaches.

Immunogenicity Assessment: The MAGE-3 (271-279) peptide serves as a model antigen in immunogenicity assays, where its capacity to elicit specific T-cell responses is quantitatively and qualitatively measured. By utilizing this peptide in ex vivo or in vitro assays, scientists can assess the immunological competence of patient-derived lymphocytes or engineered T-cell populations. These investigations help elucidate the factors influencing immune recognition of tumor antigens and support the optimization of peptide-based immunostimulatory protocols.

Peptide-Based Assay Development: As a chemically defined peptide, MAGE-3 (271-279) is widely adopted in the development and validation of peptide-specific detection assays, such as ELISPOT, tetramer staining, and cytotoxicity assays. Its use as a standard or control antigen enables the accurate quantification of antigen-specific T-cell frequencies and functional responses in experimental settings. This facilitates robust assay calibration, enhances reproducibility, and supports the comparative analysis of immune responses across different experimental systems or donor samples.

Structural and Biophysical Studies: The defined sequence and immunological relevance of this peptide make it a suitable candidate for structural and biophysical investigations. Researchers leverage synthetic MAGE-3 (271-279) to study peptide-MHC interactions, conformational dynamics, and peptide binding kinetics using techniques such as X-ray crystallography, NMR spectroscopy, or surface plasmon resonance. These studies provide molecular-level insights into antigen presentation, peptide stability, and the determinants of T-cell recognition, advancing the rational design of next-generation immunotherapeutic agents and peptide-based diagnostics.

1. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

2. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

3. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

4. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

5. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis